11 minute read
Mar. 22, 2024
Ritlecitinib (LITFULO): A Dogma-Breaking Covalent Inhibitor That Hides a Complex Discovery Story
ritlecitinib
oral, dual JAK3/TEC-family kinase inhibitor FDA approved for alopecia areata structure-based design from tofacitinib The Lancet, May 6, 2023 Pfizer, Groton, CT
Loading...
